Short-acting insulin analogues

Plank J, Siebenhofer A, Berghold A, Jeitler K, Horvath K, Mrak P, Pieber TR. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med 2005 165 1337 14. 

Radermecker RP, Scheen AJ. Continuous subcutaneous insulin infusion with short-acting insulin analogues or human regular insulin efficacy, safety, quality of life, and cost-effectiveness. Diabetes Metab Res Rev 2004 20 178-88. 

Lalli C, Ciofetta M, Del Sindaco P, Torlone E, Pampanelli S, Compagnucci P, Cartechmi MG, Bartocci L, Brunetti P, Bolli GB. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analogue hspro in variable combination with NPH insulin at mealtime. Diabetes Care 1999 22(3) 468-77. 

Short-Acting Insulin Analogues Insulin Lispro, Insulin Aspart and Insulin Glusiline... 

Siebenhofer A, Plank J, Berghold A, Horvath K, Sawicki PT, Beck P, Pieber TR. Meta-analysis of short-acting insulin analogues in adult patients with type 1 diabetes continuous subcutaneous insulin infusion versus injection therapy. Diabetologia 2004 47(11) 1895-1905. 

In vitro studies have shown a correlation of metabolic effects to insulin receptor affinity and mitogenic effects with IGF-1 receptor affinity [10], Both short-acting insulin analogues and insulin detemir have a comparable affinity with these receptors as human insulin [10],... 

Novomix 30 (contains Insulin Aspart, short acting rhinsulin analogue — see NovoRapid— as one ingredient) Novo Nordisk Diabetes mellitus 2000 (EU)... 

Human recombinant insulins and their analogues are classified as long- or short-acting insulins based on their pharmocokinetic characteristics. The pharmocokinetic properties of the common insulin preparations are given in Table 32-6. Possible approaches include (1) injection... 

NPH insulin or long-acting insulin analogues at bedtime or mixed short- and long-acting insulin analogues at the main meals 2—3 times a day should be added when HbAj is >7.0% despite maximal dose of OADs. At the start of insulin treatment, obese patients stop the sulphonylurea/meglitinide and the lean patients stop metformin. 

Humalog (Insulin lispro) Recombinant short-acting human insulin analogue produced in E. coli Engineered inversion of native B28-B29 proline-lysine sequence Eli Lilly 1996 (USA and EU)... 

NovoRapid (Insulin Aspart, short-acting rh-insulin analogue)... 

---